85,222 Shares in Enovis Co. (NYSE:ENOV) Acquired by Stephens Inc. AR

Stephens Inc. AR bought a new stake in Enovis Co. (NYSE:ENOV) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 85,222 shares of the company’s stock, valued at approximately $3,740,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. boosted its position in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after buying an additional 300 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Enovis in the third quarter worth about $55,000. FMR LLC grew its stake in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares during the last quarter. Finally, Heritage Family Offices LLP acquired a new position in shares of Enovis during the third quarter valued at about $206,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Up 1.0 %

Shares of ENOV stock opened at $44.45 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The firm has a market capitalization of $2.53 billion, a PE ratio of -20.30 and a beta of 1.94. The stock’s 50-day simple moving average is $45.82 and its 200-day simple moving average is $44.48.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $65.86.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.